李锡聪,郭瑞威

• 1:中国人民解放军联勤保障部队第九二〇医院心血管内科昆明医科大学

摘要(Abstract)：

标准可改变心血管危险因素（SMuRFs）是指吸烟状况、高血压、糖尿病和高胆固醇血症。识别和管理SMuRFs可很大程度改善心血管疾病的预后。目前心血管疾病仍然是全球死亡的主要原因。最近的研究发现没有标准可改变心血管危险因素（SMuRFs-less）在冠状动脉疾病人群中普遍存在，且比例逐年增加。SMuRFs-less的冠状动脉疾病患者在临床很容易受到忽视。近期研究表明SMuRFs-less相比SMuRFs的冠状动脉患者有更高的全因死亡率和心血管死亡率。因此，早期识别以及诊治这部分患者至关重要。本文就目前SMuRFs-less在冠状动脉疾病中的研究进展进行综述，以增加对SMuRFs-less的认识，更好地为SMuRFs-less人群提供综合全面的评估和管理。

关键词(KeyWords)： 标准可改变心血管危险因素;冠状动脉疾病;心肌梗死

Abstract:

Keywords:

基金项目(Foundation): 云南省科技厅科技计划项目（202101AY070001-030）;; 中国人民解放军联勤保障部队第九二〇医院院内科技计划（2020YGD11）

作者(Author): 李锡聪,郭瑞威

参考文献(References)：

• [1]Khot UN,Khot MB,Bajzer CT,et al.Prevalence of conventional risk factors in patients with coronary heart disease[J].JAMA,2003,290(7):898-904.DOI:10.1001/jama.290.7.898.
• [2]Figtree GA,Vernon ST,Hadziosmanovic N,et al.Mortality in STEMI patients without standard modifiable risk factors:a sexdisaggregated analysis of SWEDEHEART registry data[J].Lancet,2021,397(10279):1085-1094.DOI:10.1016/s0140-6736(21)00272-5.
• [3]王奕丹,代建南,房超,等.吸烟对急性ST段抬高型心肌梗死的影响[J].中国介入心脏病学杂志,2021,29(1):51-54.DOI:10.3969/j.issn.1004-8812.2021.01.011.
• [4]Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC guidelines for the management of arterial hypertension:the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].Eur Heart J,2013,34(28):2159-2219.DOI:10.1093/eurheartj/eht151.
• [5]American Diabetes Association.2.Classification and diagnosis of diabetes:standards of medical care in diabetes-2021[J].Diabetes Care,2021,44(Suppl 1):S15-S33.DOI:10.2337/dc21-S002.
• [6]Grundy SM,Stone NJ,Bailey AL,et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AG S/AP hA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J].Circulation,2019,139(25):e1082-e1143.DOI:10.1161/cir.0000000000000625.
• [7]吴娜琼,李建军.2018年美国心脏协会血脂管理指南解读[J].中国介入心脏病学杂志,2019,27(1):13-15.DOI:10.3969/j.issn.1004-8812.2019.01.004.
• [8]Heidemann C,Hoffmann K,Klipstein-Grobusch K,et al.Potentially modifiable classic risk factors and their impact on incident myocardial infarction:results from the EPIC-Potsdam study[J].Eur J Cardiovasc Prev Rehabil,2007,14(1):65-71.DOI:10.1097/01.hjr.0000238392.19847.4c.
• [9] Roth GA,Mensah GA,Johnson CO,et al.Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study[J].J Am Coll Cardiol,2020,76(25):2982-3021.DOI:10.1016/j.jacc.2020.11.010.
• [10]马丽媛,王增武,樊静,等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志,2022,30(7):481-496.DOI:10.3969/j.issn.1004-8812.2022.07.001.
• [11]Vernon ST,Coffey S,Bhindi R,et al.Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors[J].Eur J Prev Cardiol,2017,24(17):1824-1830.DOI:10.1177/2047487317720287.
• [12] Yusuf S,Joseph P,Rangarajan S,et al.Modifiable risk factors,cardiovascular disease,and mortality in 155 722 individuals from21 high-income,middle-income,and low-income countries(PURE):a prospective cohort study[J].Lancet,2020,395(10226):795-808.DOI:10.1016/s0140-6736(19)32008-2.
• [13]Dawber TR,Moore FE,Mann GV.Ⅱ.Coronary heart disease in the Framingham study[J].Int J Epidemiol,2015,44(6):1767-1780.DOI:10.1093/ij e/dyv346.
• [14]Kannel WB,Dawber TR,Kagan A,et al.Factors of risk in the development of coronary heart disease--six year follow-up experience.The Framingham Study[J].Ann Intern Med,1961,55:33-50.DOI:10.7326/0003-4819-55-1-33.
• [15] Keys A,Aravanis C,Blackbum H,et al.Probability of middle-aged men developing coronary heart disease in five years[J].Circulation,1972,45(4):815-828.DOI:10.1161/01.cir.45.4.815.
• [16]Wilhelmsen L,Wedel H,Tibblin G.Multivariate analysis of risk factors for coronary heart disease[J].Circulation,1973,48(5):950-958.DOI:10.1161/01.cir.48.5.950.
• [17]Kannel WB,McGee DL.Diabetes and glucose tolerance as risk factors for cardiovascular disease:the Framingham study[J].Diabetes Care,1979,2(2):120-126.DOI:10.2337/diacare.2.2.120.
• [18]Wilson PW,D'Agostino RB,Levy D,et al.Prediction of coronary heart disease using risk factor categories[J].Circulation,1998,97(18):1837-1847.DOI:10.1161/01.cir.97.18.1837.
• [19]Yusuf S,Hawken S,Ounpuu S,et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries(the INTERHEART study):case-control study[J].Lancet,2004,364(9438):937-952.DOI:10.1016/s0140-6736(04)17018-9.
• [20]Vernon ST,Coffey S,D'Souza M,et al.ST-segmentelevation myocardial infarction(STEMI)patients without standard modifiable cardiovascular risk factors-How common are they,and what are their outcomes?[J].J Am Heart Assoc,2019,8(21):e013296.DOI:10.1161/jaha.119.013296.
• [21]Li S,Gao X,Yang J,et al.Number of standard modifiable risk factors and mortality in patients with first-presentation STsegment elevation myocardial infarction:insights from China Acute Myocardial Infarction registry[J].BMC Med,2022,20(1):217.DOI:10.1186/s12916-022-02418-w.
• [22]Moledina SM,Rashid M,Nolan J,et al.Addressing disparities of care in non-ST-segment elevation myocardial infarction patients without standard modifiable risk factors:insights from a nationwide cohort study[J].Eur J Prev Cardiol,2022,29(7):1084-1092.DOI:10.1093/eurjpc/zwab200.
• [23]Figtree GA,Vernon ST,Hadziosmanovic N,et al.Mortality and cardiovascular outcomes in patients presenting with non-ST elevationmyocardial infarction despite no standard modifiable risk factors:results from the SWEDEHEART registry[J].J Am Heart Assoc,2022,11(15):e024818.DOI:10.1161/jaha.121.024818.
• [24] Shrestha B,Mochon A,Poudel B,et al.Trends and outcomes of ST-segment-elevation MI in hospitalized patients without standard modifiable cardiovascular risk factors[J].Curr Probl Cardiol,2022,47(9):101271.DOI:10.1016/j.cpcardiol.2022.101271.
• [25]Pei J,Wang X,Xing Z.Traditional cardiovascular risk factors and coronary collateral circulation:a meta-analysis[J].Front Cardiovasc Med,2021,8:743234.DOI:10.3389/fcvm.2021.743234.
• [26] Mazhar J,Ekstr?m K,Kozor R,et al.Cardiovascular magnetic resonance characteristics and clinical outcomes of patients with ST-elevation myocardial infarction and no standard modifiable risk factors-A DANA MI-3 sub study[J].Front Cardiovasc Med,2022,9:945815.DOI:10.3389/fcvm.2022.945815.
• [27]Figtree GA,Redfors B,Kozor R,et al.Clinical outcomes in patients with ST-segment elevation MI and no standard modifiable cardiovascular risk factors[J].JACC Cardiovasc Interv,2022,15(11):1167-1175.DOI:10.1016/j.jcin.2022.03.036.
• [28]Sia CH,Ko J,Zheng H,et al.Comparison of mortality outcomes in acute myocardial infarction patients with or without standard modifiable cardiovascular risk factors[J].Front Cardiovasc Med,2022,9:876465.DOI:10.3389/fcvm.2022.876465.
• [29]Kong G,Chew NWS,Ng CH,et al.Prognostic outcomes in acute myocardial infarction patients without standard modifiable risk factors:a multiethnic study of 8,680 Asian patients[J].Front Cardiovasc Med,2022,9:869168.DOI:10.3389/fcvm.2022.869168.
• [30]Sokhal BS,Matetic A,Paul TK,et al.Management and outcomes of patients admitted with type 2 myocardial infarction with and without standard modifiable risk factors[J].Int J Cardiol,2023,371:391-396.DOI:10.1016/j.ijcard.2022.09.037.
• [31]Chen X,Liu HX,Yu XQ,et al.Standard modifiable cardiovascular risk factors and prognosis of acute coronary syndrome in younger patients[J].J Coll Physicians Surg Pak,2021,31(12):1394-1398.DOI:10.29271/jcpsp.2021.12.1394.
• [32] Wang L,Cong HL,Zhang JX,et al.Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors[J].Front Cardiovasc Med,2022,9:916085.DOI:10.3389/fcvm.2022.916085.
• [33]Won KB,Park GM,Yang YJ,et al.Independent role of low-density lipoprotein cholesterol in subclinical coronary atherosclerosis in the absence of traditional cardiovascular risk factors[J].Eur Heart J Cardiovasc Imaging,2019,20(8):866-872.DOI:10.1093/ehjci/jez091.
• [34]Mazhar J,Figtree G,Vernon ST,et al.Progression of coronary atherosclerosis in patients without standard modifiable risk factors[J].Am J Prev Cardiol,2020,4:100116.DOI:10.1016/j.ajpc.2020.100116.
• [35] Moysidis DV,Daios S,Anastasiou V,et al.Association of clinical,laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors-rationale and design of the"BeyondSMuRFs Study"[J].BMC Cardiovasc Disord,2023,23(1):149.DOI:10.1186/s12872-023-03180-4.
• [36] Kott KA,Vernon ST,Hansen T,et al.Biobanking for discovery of novel cardiovascular bio markers using imagingquantified disease burden:protocol for the longitudinal,prospective,BioHEART-CT cohort study[J].BMJ Open,2019,9(9):e028649.DOI:10.1136/bmjopen-2018-028649.